April 10 (SeeNews) - Tokyo-based Eisai Co. said its U.K. subsidiary Eisai Europe Limited has entered into an agreement with Swiss-based PharmaSwiss to promote and distribute the company's novel anticancer agent Halaven in a number of Central and Eastern European countries.